Should You Worry About the Latest Wave of Bad News from Pfizer?
Published
Earlier in the pandemic, Pfizer (PFE 1.91%) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on growth -- and pushing some investors to flee the stock. That's because, as we head toward a…
#pfe #pfizer #seagen